PTI’s Oxytrex “Worth One More Shot” After Phase III Study Spoiled By Vioxx
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inappropriate enrollment of former Vioxx patients in Pain Therapeutics’ Phase III trial of Oxytrex for severe osteoarthritic pain undermined the study’s statistical power and necessitates a new trial, according to PTI.